IC-SDV 2018: Diane Webb (BizInt) Challenges in Visualizing Pharmaceutical Information - Part III: Smart Strategy Dashboards
•
1 like•977 views
This paper revisits the issues discussed in our 2013 and 2016 presentations "Challenges in Visualizing Pharmaceutical Business Information," where we analyzed some of the unique challenges in visualizing competitive intelligence information for the pharmaceutical industry. A key challenge for pharmaceutical companies is to evaluate the competitive landscapes for drug launches many years in the future, based on a combination of publicly available drug pipeline and clinical trials data and internal company knowledge. This information is often conveyed in hand-drawn PowerPoint slides, which are very time consuming to create and update as the competitive landscape changes. In this year's presentation, we'll discuss the development of a "dashboard" of visualizations (piano charts, trial completion timelines, maps, etc.) to facilitate the analysis and visualization of competitive drug landscapes.
Recommended
Recommended
More Related Content
What's hot
What's hot (20)
Similar to IC-SDV 2018: Diane Webb (BizInt) Challenges in Visualizing Pharmaceutical Information - Part III: Smart Strategy Dashboards
Similar to IC-SDV 2018: Diane Webb (BizInt) Challenges in Visualizing Pharmaceutical Information - Part III: Smart Strategy Dashboards (20)
More from Dr. Haxel Consult
More from Dr. Haxel Consult (20)
Recently uploaded
Recently uploaded (20)
IC-SDV 2018: Diane Webb (BizInt) Challenges in Visualizing Pharmaceutical Information - Part III: Smart Strategy Dashboards
- 1. Challenges in Visualizing Pharmaceutical Information – Smart Strategy Dashboards Patents & IP Sequences | Clinical Trials | Drug Pipelines www.bizint.com IC-SDV 2018, Nice Diane Q. Webb, President 23 April 2018
- 2. © 2018 BizInt Solutions, Inc | www.bizint.com 2 The Problem: Visualizations developed for scientific and patent data do not do a good job of “telling the story” when applied to drug pipeline data and often need significant changes. 2013 II-SDV Paper: Challenges in Visualizing Pharmaceutical Business Information
- 3. © 2018 BizInt Solutions, Inc | www.bizint.com 3 The Drug Development “Pipeline” At each stage of the pipeline, companies need information on drugs in development to make both business and research decisions.
- 4. © 2018 BizInt Solutions, Inc | www.bizint.com 4 Clinical Trials Phases in the Drug Pipeline
- 5. © 2018 BizInt Solutions, Inc | www.bizint.com 5 Source: Edi et al., Yang et al, Search Technology Examples of Technical Visualizations Found on the web
- 6. © 2018 BizInt Solutions, Inc | www.bizint.com 6 Source: Roche, Ligand, AmgenOncology websites Examples of pharma pipeline visualizations Found on the web
- 7. © 2018 BizInt Solutions, Inc | www.bizint.com 7 • Worked with a customer to automate the creation of labor intensive, hand-drawn product launch timelines. • Result: Attractive computer- drawn visualizations… • That required a lot of data preparation to create. 2016 II-SDV Paper: Competitive Launch Landscapes More info: bizint.com/slides
- 8. © 2018 BizInt Solutions, Inc | www.bizint.com 8 • Decision maker who needs the visualization. • Competitive intelligence analyst who knows the disease area and company interests. • Search specialist to collect the correct data. • Sophisticated tool user who can manipulate the data. • In some companies, it can be hard to assemble these skills. Lessons Learned – You need a team
- 9. © 2018 BizInt Solutions, Inc | www.bizint.com 9 • Designed for analysts who don’t have the time to learn some or all of the BizInt tools. • BizInt will use the BizInt Smart Charts tools to build BizInt Smart Strategy Dashboards for you. • Smart Strategy Dashboards is a set of visualizations that address several questions about your topic: Who? What? Where? When? BizInt Smart Strategy Dashboards (BizDash)
- 10. © 2018 BizInt Solutions, Inc | www.bizint.com 10
- 11. © 2018 BizInt Solutions, Inc | www.bizint.com 11
- 12. © 2018 BizInt Solutions, Inc | www.bizint.com 12
- 13. © 2018 BizInt Solutions, Inc | www.bizint.com 13
- 14. © 2018 BizInt Solutions, Inc | www.bizint.com 14
- 15. © 2018 BizInt Solutions, Inc | www.bizint.com 15 • There is some interest in an interactive visualization that people can explore… • But the primary requirement is for a PowerPoint slide. • An image in a PowerPoint slide is okay… • But you’d really like to create PowerPoint objects (so you can customize the presentation and make final edits.) Lessons Learned – It’s all about
- 16. © 2018 BizInt Solutions, Inc | www.bizint.com 16 Biological Testing Merkel cell carcinoma therapies Vironika Preclinical CK-301 TG Therapeutics ETBX-051 NantWorks ETBX-061 NantWorks ipilimumab Bristol-Myers Squibb Co LTvax APCure Merkel cell polyomavirus inhibitors Vironika Phase I BGB-A317 Celgene ID-G100 Immune Design pasireotide Novartis SIRPa-Fc Trillium Therapeutics utomilumab Pfizer Phase II ALT 803 Altor BioScience Corporation cabozantinib S-malate Exelixis CST-101 NantWorks F16-IL2 Philogen MCPyV vaccine Fred Hutchinson Cancer Research Center nivolumab Ono Pharmaceutical Co Ltd pazopanib GlaxoSmithKline plc pembrolizumab Merck & Co PEN-221 Tarveda Therapeutics sapanisertib Intellikine talimogene laherparepvec BioVex Inc tavokinogene telsaplasmid OncoSec Medical Launched avelumab Merck KGaA Discontinued lorvotuzumab mertansine ImmunoGen No Development Reported ATN-161 Attenuon tivantinib ArQule Type of molecule Antibody Biological, other Cell & gene therapy Protein & peptide Small molecule therapeutic Vaccine Merkel cell carcinoma (MCC) pipeline: Phase for MCC and type of molecule Background: Data from Pharmaprojects, R&D Insight, Cortellis was integrated in BizInt Smart Charts, cleaned up and visualized with VP-SCE. Phase for MCC was extracted from the Drug Development Phase field. Values shown are those reported by the databases. Drugs color-coded by a chosen field Labeled by drug name and a chosen field Option for hyperlink to pipeline record “Piano Chart” – PowerPoint visualization Each column contains the drugs in that phase
- 17. © 2018 BizInt Solutions, Inc | www.bizint.com 17 Biological Testing Merkel cell carcinoma therapies Vironika Preclinical CK-301 TG Therapeutics ETBX-051 NantWorks ETBX-061 NantWorks ipilimumab Bristol-Myers Squibb Co LTvax APCure Merkel cell polyomavirus inhibitors Vironika Phase I BGB-A317 Celgene ID-G100 Immune Design pasireotide Novartis SIRPa-Fc Trillium Therapeutics utomilumab Pfizer Phase II ALT 803 Altor BioScience Corporation cabozantinib S-malate Exelixis CST-101 NantWorks F16-IL2 Philogen MCPyV vaccine Fred Hutchinson Cancer Research Center nivolumab Ono Pharmaceutical Co Ltd pazopanib GlaxoSmithKline plc pembrolizumab Merck & Co PEN-221 Tarveda Therapeutics sapanisertib Intellikine talimogene laherparepvec BioVex Inc tavokinogene telsaplasmid OncoSec Medical Launched avelumab Merck KGaA Discontinued lorvotuzumab mertansine ImmunoGen No Development Reported ATN-161 Attenuon tivantinib ArQule Type of molecule Antibody Biological, other Cell & gene therapy Protein & peptide Small molecule therapeutic Vaccine Merkel cell carcinoma (MCC) pipeline: Phase for MCC and type of molecule Background: Data from Pharmaprojects, R&D Insight, Cortellis was integrated in BizInt Smart Charts, cleaned up and visualized with VP-SCE. Phase for MCC was extracted from the Drug Development Phase field. Values shown are those reported by the databases. Annotating the Piano Chart in PowerPoint Key Competitor Add box outlines to indicate Key Competitors
- 18. © 2018 BizInt Solutions, Inc | www.bizint.com 18 Biological Testing Merkel cell carcinoma therapies Vironika Preclinical CK-301 TG Therapeutics ETBX-051 NantWorks ETBX-061 NantWorks ipilimumab Bristol-Myers Squibb Co LTvax APCure Merkel cell polyomavirus inhibitors Vironika Phase I BGB-A317 Celgene ID-G100 Immune Design pasireotide Novartis SIRPa-Fc Trillium Therapeutics utomilumab Pfizer Phase II ALT 803 Altor BioScience Corporation cabozantinib S-malate Exelixis CST-101 NantWorks F16-IL2 Philogen MCPyV vaccine Fred Hutchinson Cancer Research Center nivolumab Ono Pharmaceutical Co Ltd pazopanib GlaxoSmithKline plc pembrolizumab Merck & Co PEN-221 Tarveda Therapeutics sapanisertib Intellikine talimogene laherparepvec BioVex Inc tavokinogene telsaplasmid OncoSec Medical Launched avelumab Merck KGaA Discontinued lorvotuzumab mertansine ImmunoGen No Development Reported ATN-161 Attenuon tivantinib ArQule Type of molecule Antibody Biological, other Cell & gene therapy Protein & peptide Small molecule therapeutic Vaccine Merkel cell carcinoma (MCC) pipeline: Phase for MCC and type of molecule Background: Data from Pharmaprojects, R&D Insight, Cortellis was integrated in BizInt Smart Charts, cleaned up and visualized with VP-SCE. Phase for MCC was extracted from the Drug Development Phase field. Values shown are those reported by the databases. Annotating the Piano Chart in PowerPoint Key Competitor Another way to indicate Key Competitors
- 19. © 2018 BizInt Solutions, Inc | www.bizint.com 19 • Everyone wants an “easy” button! • We’ve made the actual drawing of the visualizations easy. • But a lot of data preparation is necessary -- Lessons Learned – It’s not “Easy” • Filter data to the most critical items (e.g. “Key Drugs”) • Group values to create useful categories. • Shorten labels to fit. • Apply expertise for values not in the data.
- 20. © 2018 BizInt Solutions, Inc | www.bizint.com 20 Data Preparation for the Launch Timeline Group items into a few categories Launch Date is not a field in the data! Group items into a few colors.
- 21. © 2018 BizInt Solutions, Inc | www.bizint.com 21 Phase 1 AEOL-10150 AEOL-10150 AEOL-10150 allogeneictumor lysate-pulsedautologous dendritic cells allogeneictumor lysate-pulsedautologous dendritic cells allogeneictumor lysate-pulsedautologous dendritic cells allogeneictumor lysate-pulsedautologous dendritic cells allogeneictumor lysate-pulsedautologous dendritic cells allogeneictumor lysate-pulsedautologous dendritic cells allogeneictumor lysate-pulsedautologous dendritic cells ARGX-110 ARGX-110 ARGX-110 ARGX-110 BGB-A317 BGB-A317 BGB-A317 BGB-A317 BGB-A317 BGB-A317 BGB-A317 CB-839 CB-839 CB-839 CK-301 CK-301 CK-301 CK-301 CK-301 dasatinib dasatinib dasatinib dasatinib dasatinib FP-1039 FP-1039 FP-1039 FP-1039 FP-1039 FP-1039 gene therapy GL-ONC1 GL-ONC1 GL-ONC1 GL-ONC1 GL-ONC1 imatinib imatinib imatinib imatinib imatinib imatinib LMB-100 LMB-100 LMB-100 LMB-100 LMB-100 LY-3023414 LY-3023414 MesoCART MesoCART MesoCART MesoCART MesoCART MesoCART MesoCART MTG-202 MTG-202 MTG-202 MV-NIS MV-NIS MV-NIS MV-NIS MV-NIStherapy MV-NIStherapy MV-NIStherapy MV-NIStherapy MV-NIStherapy roniciclib roniciclib roniciclib trametinib trametinib trametinib trametinib Phase 1/2 JTCR-016 JTCR-016 JTCR-016 JTCR-016 JTCR-016 pevonedistat pevonedistat pevonedistat Phase 2 aglatimagene besadenovec aglatimagene besadenovec aglatimagene besadenovec amatuximab amatuximab amatuximab amatuximab amatuximab amatuximab anti-mesothelin CAR engineeredpbl therapy anti-mesothelin CAR engineeredpbl therapy anti-mesothelin CAR engineeredpbl therapy anti-mesothelin CAR engineeredpbl therapy atezolizumab atezolizumab atezolizumab atezolizumab atezolizumab atezolizumab atezolizumab atezolizumab AZD-4547 AZD-4547 AZD-4547 AZD-4547 BNC-105P BNC-105P BNC-105P BNC-105P brentuximab vedotin brentuximab vedotin brentuximab vedotin brentuximab vedotin brentuximab vedotin brentuximab vedotin brentuximab vedotin brentuximab vedotin brentuximab vedotin carfilzomib carfilzomib carfilzomib carfilzomib carfilzomib carfilzomib CBP-501 CBP-501 CBP-501 CRS-207 CRS-207 CRS-207 CRS-207 CRS-207 defactinib defactinib defactinib durvalumab durvalumab durvalumab durvalumab durvalumab durvalumab durvalumab + tremelimumab durvalumab + tremelimumab durvalumab + tremelimumab durvalumab + tremelimumab durvalumab + tremelimumab durvalumab + tremelimumab galinpepimut-S galinpepimut-S galinpepimut-S galinpepimut-S galinpepimut-S gemcitabine prodrug gemcitabine prodrug gemcitabine prodrug gemcitabine prodrug gemcitabine prodrug HSV-1716 HSV-1716 HSV-1716 HSV-1716 K562/GM-CSF K562/GM-CSF K562/GM-CSF K562/GM-CSF lurbinectedin lurbinectedin lurbinectedin Minerval Minerval Minerval miR-15/16 mimics miR-15/16 mimics miR-15/16 mimics miR-15/16 mimics miR-15/16 mimics miR-15/16 mimics MTG-201 MTG-201 MTG-201 napabucasin napabucasin napabucasin ONCOS-102 ONCOS-102 ONCOS-102 ONCOS-102 pegargiminase pegargiminase pegargiminase pegargiminase pegargiminase pembrolizumab pembrolizumab pembrolizumab pembrolizumab pembrolizumab pembrolizumab pembrolizumab pembrolizumab porfimer sodium porfimer sodium SS SS SS SS SS sunitinib sunitinib sunitinib tazemetostat tazemetostat trabectedin trabectedin trabectedin trabectedin trabectedin trabectedin TRC-102 TRC-102 TRC-102 tremelimumab tremelimumab tremelimumab tremelimumab tremelimumab tremelimumab TroVax TroVax TroVax TroVax TroVax vinorelbine vinorelbine vinorelbine vinorelbine WT1-targeted autologous dendritic cell vaccine WT1-targeted autologous dendritic cell vaccine WT1-targeted autologous dendritic cell vaccine WT1-targeted autologous dendritic cell vaccine YSCMA YSCMA YSCMA YSCMA YSCMA YSCMA zoledronic acid zoledronic acid zoledronic acid zoledronic acid zoledronic acid Phase 3 ipilimumab ipilimumab ipilimumab ipilimumab ipilimumab ipilimumab ipilimumab NGR-hTNF NGR-hTNF NGR-hTNF NGR-hTNF NGR-hTNF nintedanib nintedanib nintedanib nintedanib nivolumab nivolumab nivolumab nivolumab nivolumab nivolumab nivolumab Preregistration pemetrexed pemetrexed pemetrexed Launched Pemetrexed- CJ Healthcare pemetrexeddisodium pemetrexeddisodium pemetrexeddisodium pemetrexeddisodium pemetrexeddisodium raltitrexed raltitrexed raltitrexed Technologies AntibodyAntibody conjugatedAntibody fragmentAntigenAntigenpresentationsystemBacteria recombinantBiological therapeuticCapsule formulationCell therapyChimeric antibodyChimeric antigenreceptor T cell therapyChimeric monoclonal antibodyDrug combinationFilmcoatingFormulation powderFreeze dryingImagingImmuno-oncologyImmunoglobulin-GInfusionInjectable formulationIntradermal formulationIntramuscular formulationIntraperitoneal formulationIntratumoral formulationIntravenousformulationLipidLiquid formulationLymphocyteMonoclonal antibodyNanoparticle formulationinjectableNatural productNucleotide and derivativesOligonucleotideOral formulationParenteral formulationunspecifiedPEGylated formulationPeptideProdrugProteinconjugatedProteinfusionProteinrecombinantReceptor chimericRecombinant enzymeSmall molecule therapeuticSolutionSubcutaneous formulationSystemicformulationunspecifiedT-lymphocyteTablet formulationToxin binding proteinTumor antigenTumor antigentherapeuticVirusrecombinant Piano Chart - Mesothelioma Piano Chart without data preparation This is horrible!
- 22. © 2018 BizInt Solutions, Inc | www.bizint.com 22 Piano Chart without data preparation Phase 1 AEOL-10150 AEOL-10150 AEOL-10150 allogeneictumor lysate-pulsedautologous dendritic cells allogeneictumor lysate-pulsedautologous dendritic cells allogeneictumor lysate-pulsedautologous dendritic cells allogeneictumor lysate-pulsedautologous dendritic cells allogeneictumor lysate-pulsedautologous dendritic cells allogeneictumor lysate-pulsedautologous dendritic cells allogeneictumor lysate-pulsedautologous dendritic cells ARGX-110 ARGX-110 ARGX-110 ARGX-110 BGB-A317 BGB-A317 BGB-A317 BGB-A317 BGB-A317 BGB-A317 BGB-A317 CB-839 CB-839 CB-839 CK-301 CK-301 CK-301 CK-301 CK-301 dasatinib dasatinib dasatinib dasatinib dasatinib FP-1039 FP-1039 FP-1039 FP-1039 FP-1039 FP-1039 gene therapy GL-ONC1 GL-ONC1 GL-ONC1 GL-ONC1 GL-ONC1 imatinib imatinib imatinib imatinib imatinib imatinib LMB-100 LMB-100 LMB-100 LMB-100 LMB-100 LY-3023414 LY-3023414 MesoCART MesoCART MesoCART MesoCART MesoCART MesoCART MesoCART MTG-202 MTG-202 MTG-202 MV-NIS MV-NIS MV-NIS MV-NIS MV-NIStherapy MV-NIStherapy MV-NIStherapy MV-NIStherapy MV-NIStherapy roniciclib roniciclib roniciclib trametinib trametinib trametinib trametinib Phase 1/2 JTCR-016 JTCR-016 JTCR-016 JTCR-016 JTCR-016 pevonedistat pevonedistat pevonedistat Phase 2 aglatimagene besadenovec aglatimagene besadenovec aglatimagene besadenovec amatuximab amatuximab amatuximab amatuximab amatuximab amatuximab anti-mesothelin CAR engineeredpbl therapy anti-mesothelin CAR engineeredpbl therapy anti-mesothelin CAR engineeredpbl therapy anti-mesothelin CAR engineeredpbl therapy atezolizumab atezolizumab atezolizumab atezolizumab atezolizumab atezolizumab atezolizumab atezolizumab AZD-4547 AZD-4547 AZD-4547 AZD-4547 BNC-105P BNC-105P BNC-105P BNC-105P brentuximab vedotin brentuximab vedotin brentuximab vedotin brentuximab vedotin brentuximab vedotin brentuximab vedotin brentuximab vedotin brentuximab vedotin brentuximab vedotin carfilzomib carfilzomib carfilzomib carfilzomib carfilzomib carfilzomib CBP-501 CBP-501 CBP-501 CRS-207 CRS-207 CRS-207 CRS-207 CRS-207 defactinib defactinib defactinib durvalumab durvalumab durvalumab durvalumab durvalumab durvalumab durvalumab + tremelimumab durvalumab + tremelimumab durvalumab + tremelimumab durvalumab + tremelimumab durvalumab + tremelimumab durvalumab + tremelimumab galinpepimut-S galinpepimut-S galinpepimut-S galinpepimut-S galinpepimut-S gemcitabine prodrug gemcitabine prodrug gemcitabine prodrug gemcitabine prodrug gemcitabine prodrug HSV-1716 HSV-1716 HSV-1716 HSV-1716 K562/GM-CSF K562/GM-CSF K562/GM-CSF K562/GM-CSF lurbinectedin lurbinectedin lurbinectedin Minerval Minerval Minerval miR-15/16 mimics miR-15/16 mimics miR-15/16 mimics miR-15/16 mimics miR-15/16 mimics miR-15/16 mimics MTG-201 MTG-201 MTG-201 napabucasin napabucasin napabucasin ONCOS-102 ONCOS-102 ONCOS-102 ONCOS-102 pegargiminase pegargiminase pegargiminase pegargiminase pegargiminase pembrolizumab pembrolizumab pembrolizumab pembrolizumab pembrolizumab pembrolizumab pembrolizumab pembrolizumab porfimer sodium porfimer sodium SS SS SS SS SS sunitinib sunitinib sunitinib tazemetostat tazemetostat trabectedin trabectedin trabectedin trabectedin trabectedin trabectedin TRC-102 TRC-102 TRC-102 tremelimumab tremelimumab tremelimumab tremelimumab tremelimumab tremelimumab TroVax TroVax TroVax TroVax TroVax vinorelbine vinorelbine vinorelbine vinorelbine WT1-targeted autologous dendritic cell vaccine WT1-targeted autologous dendritic cell vaccine WT1-targeted autologous dendritic cell vaccine WT1-targeted autologous dendritic cell vaccine YSCMA YSCMA YSCMA YSCMA YSCMA YSCMA zoledronic acid zoledronic acid zoledronic acid zoledronic acid zoledronic acid Phase 3 ipilimumab ipilimumab ipilimumab ipilimumab ipilimumab ipilimumab ipilimumab NGR-hTNF NGR-hTNF NGR-hTNF NGR-hTNF NGR-hTNF nintedanib nintedanib nintedanib nintedanib nivolumab nivolumab nivolumab nivolumab nivolumab nivolumab nivolumab Preregistration pemetrexed pemetrexed pemetrexed Launched Pemetrexed- CJ Healthcare pemetrexeddisodium pemetrexeddisodium pemetrexeddisodium pemetrexeddisodium pemetrexeddisodium raltitrexed raltitrexed raltitrexed Technologies AntibodyAntibody conjugatedAntibody fragmentAntigenAntigenpresentationsystemBacteria recombinantBiological therapeuticCapsule formulationCell therapyChimeric antibodyChimeric antigenreceptor T cell therapyChimeric monoclonal antibodyDrug combinationFilmcoatingFormulation powderFreeze dryingImagingImmuno-oncologyImmunoglobulin-GInfusionInjectable formulationIntradermal formulationIntramuscular formulationIntraperitoneal formulationIntratumoral formulationIntravenousformulationLipidLiquid formulationLymphocyteMonoclonal antibodyNanoparticle formulationinjectableNatural productNucleotide and derivativesOligonucleotideOral formulationParenteral formulationunspecifiedPEGylated formulationPeptideProdrugProteinconjugatedProteinfusionProteinrecombinantReceptor chimericRecombinant enzymeSmall molecule therapeuticSolutionSubcutaneous formulationSystemicformulationunspecifiedT-lymphocyteTablet formulationToxin binding proteinTumor antigenTumor antigentherapeuticVirusrecombinant Piano Chart - Mesothelioma Technologies Antibody Antibody conjugated Antibody fragment Antigen Antigen presentation Bacteria recombinant Biological therapeutic Capsule formulation Cell therapy Need to refine Technologies for a more effective key
- 23. © 2018 BizInt Solutions, Inc | www.bizint.com 23 Phase I AEOL-10150 ARGX-110 BGB-A317 CB-839 CK-301 dasatinib FP-1039 gene therapy GL-ONC1 imatinib LMB-100 LY-3023414 MesoCART MesoPher MTG-202 MV-NIS MV-NIStherapy roniciclib trametinib Phase I/II JTCR-016 pevonedistat Phase II aglatimagene besadenovec amatuximab anti-mesothelin CAR atezolizumab AZD-4547 BNC-105P brentuximab vedotin carfilzomib CAT-5001 CBP-501 CRS-207 defactinib durvalumab durvalumab + tremelimumab galinpepimut-S gemcitabine prodrug HSV-1716 K562/GM-CSF lurbinectedin Minerval miR-15/16 mimics MTG-201 napabucasin ONCOS-102 pegargiminase pembrolizumab porfimer sodium sunitinib tazemetostat trabectedin TRC-102 tremelimumab TroVax vinorelbine WT1-targeted vaccine YSCMA zoledronic acid Phase III ipilimumab NGR-hTNF nintedanib nivolumab Launched pemetrexed raltitrexed Drug type Antibodies Cancer-vaccines Cell/Gene therapies Oncolytic viruses Peptides/Proteins Small molecules Piano Chart Mesothelioma Piano Chart – creating a useful color key Grouping Technology terms into Drug Types creates a useful key
- 24. © 2018 BizInt Solutions, Inc | www.bizint.com 24 Phase 1 AEOL-10150 ARGX-110 BGB-A317 CB-839 CK-301 dasatinib FP-1039 gene therapy GL-ONC1 imatinib LMB-100 LY-3023414 MesoCART MesoPher MTG-202 MV-NIS MV-NIS therapy roniciclib trametinib Phase 1/2 JTCR-016 pevonedistat Phase 2 aglatimagene besadenovecamatuximab anti-mesothelin CAR atezolizumab AZD-4547 BNC-105P brentuximab vedotin carfilzomib CAT-5001 CBP-501 CRS-207 defactinib durvalumab durvalumab + tremelimumabgalinpepimut-S gemcitabine prodrug HSV-1716 K562/GM-CSF Phase 2 lurbinectedin Minerval miR-15/16 mimics MTG-201 napabucasin ONCOS-102 pegargiminase pembrolizumab porfimer sodium sunitinib tazemetostat trabectedin TRC-102 tremelimumab TroVax vinorelbine WT1-targeted vaccine YSCMA zoledronic acid Phase 3 ipilimumab NGR-hTNF nintedanib nivolumab Launched pemetrexed raltitrexed Drug type Antibodies Cancer vaccines Cell/Gene therapies Oncolytic viruses Peptides/Proteins Small molecules Piano Chart – Mesothelioma Piano Chart – how to display large columns Display Phase 2 drugs in two columns
- 25. © 2018 BizInt Solutions, Inc | www.bizint.com 25 • Color code key should have no more than 8 colors; 5-6 is better. • For key values with a progression (e.g. phase, trial status) choose a sequential color scheme. • For key values with no order (e.g. companies) choose a qualitative color scheme. Lessons Learned – Choose the Right Colors
- 26. © 2018 BizInt Solutions, Inc | www.bizint.com 26 Biological Testing Merkel cell carcinoma therapies Vironika Preclinical CK-301 TG Therapeutics ETBX-051 NantWorks ETBX-061 NantWorks ipilimumab Bristol-Myers Squibb Co LTvax APCure Merkel cell polyomavirus inhibitors Vironika Phase I BGB-A317 Celgene ID-G100 Immune Design pasireotide Novartis SIRPa-Fc Trillium Therapeutics utomilumab Pfizer Phase II ALT 803 Altor BioScience Corporation cabozantinib S-malate Exelixis CST-101 NantWorks F16-IL2 Philogen MCPyV vaccine Fred Hutchinson Cancer Research Center nivolumab Ono Pharmaceutical Co Ltd pazopanib GlaxoSmithKline plc pembrolizumab Merck & Co PEN-221 Tarveda Therapeutics sapanisertib Intellikine talimogene laherparepvec BioVex Inc tavokinogene telsaplasmid OncoSec Medical Launched avelumab Merck KGaA Discontinued lorvotuzumab mertansine ImmunoGen No Development Reported ATN-161 Attenuon tivantinib ArQule Type of molecule Antibody Biological, other Cell & gene therapy Protein & peptide Small molecule therapeutic Vaccine Merkel cell carcinoma (MCC) pipeline: by Type of Molecule Background: Data from Pharmaprojects, R&D Insight, Cortellis was integrated in BizInt Smart Charts, cleaned up and visualized with VP-SCE. Phase for MCC was extracted from the Drug Development Phase field. Values shown are those reported by the databases. Piano chart: Qualitative Color Code Key
- 27. © 2018 BizInt Solutions, Inc | www.bizint.com 27 Merkel cell carcinoma (MCC) trials: by Trial Status Piano chart: Sequential Color Code Key
- 28. © 2018 BizInt Solutions, Inc | www.bizint.com 28 • The one that “tells the story” for your topic and data. • Try different visualizations and different categorizations/color code keys. • A visualization that works well for one data set might not be very interesting for your next project. Lessons Learned – The Best Visualization is… Phase I Phase I/II Phase II aglatimagene besadenovec amatuximab anti-mesothelin CAR atezolizumab AZD-4547 BNC-105P brentuximab vedotin carfilzomib CAT-5001 CBP-501 CRS-207 defactinib durvalumab durvalumab + tremelimumab galinpepimut-S gemcitabine prodrug HSV-1716 K562/GM-CSF lurbinectedin Minerval miR-15/16 mimics MTG-201 napabucasin ONCOS-102 pegargiminase pembrolizumab porfimer sodium sunitinib tazemetostat trabectedin TRC-102 tremelimumab TroVax vinorelbine WT1-targeted vaccine YSCMA zoledronic acid Phase III Launched
- 29. © 2018 BizInt Solutions, Inc | www.bizint.com 29 Sample “bulls-eye” charts - 2013 II-SDV Paper – Found on the web
- 30. © 2018 BizInt Solutions, Inc | www.bizint.com 30 Phase 1 AEOL-10150 ARGX-110 BGB-A317 CB-839 CK-301 dasatinib FP-1039 gene therapy GL-ONC1 imatinib LMB-100 LY-3023414 MesoCART MesoPher MTG-202 MV-NIS MV-NIS therapy roniciclib trametinib Phase 1/2 JTCR-016 pevonedistat Phase 2 aglatimagene besadenovecamatuximab anti-mesothelin CAR atezolizumab AZD-4547 BNC-105P brentuximab vedotin carfilzomib CAT-5001 CBP-501 CRS-207 defactinib durvalumab durvalumab + tremelimumabgalinpepimut-S gemcitabine prodrug HSV-1716 K562/GM-CSF Phase 2 lurbinectedin Minerval miR-15/16 mimics MTG-201 napabucasin ONCOS-102 pegargiminase pembrolizumab porfimer sodium sunitinib tazemetostat trabectedin TRC-102 tremelimumab TroVax vinorelbine WT1-targeted vaccine YSCMA zoledronic acid Phase 3 ipilimumab NGR-hTNF nintedanib nivolumab Launched pemetrexed raltitrexed Drug type Antibodies Cancer vaccines Cell/Gene therapies Oncolytic viruses Peptides/Proteins Small molecules Piano Chart – Mesothelioma Mesothelioma pipeline in a Piano Chart Would a bulls-eye be better for this dataset?
- 31. © 2018 BizInt Solutions, Inc | www.bizint.com 31 amatuximab ARGX-110 atezolizumab BGB-A317 brentuximab vedotin CAT-5001 CK-301 durvalumab durvalumab + tremelimumab ipilimumab nivolumab pembrolizumab tremelimumab YSCMA CRS-207 galinpepimut-S JTCR-016 K562/GM-CSF MesoPher TroVax WT1 vaccine aglatimagene besadenovec anti-mesothelin CAR gene therapy MesoCART miR-15/16 mimics MTG-201 MTG-202 GL-ONC1 HSV-1716 MV-NIS MV-NIS therapy ONCOS-102 CBP-501 FP-1039 LMB-100 NGR-hTNF pegargiminase AEOL-10150 AZD-4547 BNC-105P carfilzomib CB-839 dasatinib defactinib gemcitabine prodrug imatinib lurbinectedin LY-3023414 Minerval napabucasin nintedanib pemetrexed pevonedistat porfimer sodium raltitrexed roniciclib sunitinib tazemetostat trabectedin trametinib TRC-102 vinorelbine zoledronic acid Small molecules Cell/Gene therapies Antibodies Peptides/Proteins Cancer vaccines Oncolytic viruses Mesothelioma – Bulls-Eye created for PowerPoint Marketed Phase 3 Phase 2 Phase 1 Now part of:
- 32. Thank you to my “chef” colleagues at BizInt and VantagePoint! Matt Eberle John Willmore, Joe Johnson, Bertha Adamson and Jon Garner, Paul Frey, Nils Newman